| Richard Mark Hatfield, MD | |
|
331 Laidley St, Ste 301, Charleston, WV 25301-1605 | |
| (304) 346-4400 | |
| (304) 346-0704 |
| Full Name | Richard Mark Hatfield |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 41 Years |
| Location | 331 Laidley St, Charleston, West Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316941297 | NPI | - | NPPES |
| 0796812 | Medicaid | OH | |
| 0095043000 | Medicaid | WV | |
| 64697303 | Medicaid | KY |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Francis Hospital | Charleston, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Retina Consultants Pllc | 3375636178 | 6 |
| Retina Consultants Pllc | 3375636178 | 6 |
News Archive
August marks the start of misery for as many as one in five Americans who suffer from hay fever, also called seasonal allergic rhinitis. That's because ragweed, the main cause of hay fever, begins blooming around mid-August and in one day each plant can produce a million pollen grains that can travel for miles from its source.
Great Lakes NeuroTechnologies announced today they will be using a $1.5M award from NIH to expand their Parkinson's monitoring technology to mobile applications. Repositioning GLNT's Kinesia product line with mobile apps strategically aligns with growing trends in domestic and international healthcare landscapes regarding accessibility, costs, reimbursement, and regulatory policies.
San Diego-based Concerro, Inc., the market leader in enterprise-wide hospital shift and disaster workforce management software, has enhanced its CommandAware® hospital incident management system by adding a new location-based intelligence tool to help clients identify and interact with regional data in a more efficient way.
USA Today reports that President Obama is spending the weekend wrapping up what he himself calls a bruising campaign season. The president, trying to stave off Democratic losses in the U.S. House and Senate, hits three cities today to urge voters to stick with his health care, energy, and economic recovery plans.
Enobia Pharma announced today the initiation of a Phase 2 clinical study of ENB-0040, a bone-targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). The six-month study will assess the safety, efficacy and pharmacokinetics of ENB-0040 in up to 12 children with HPP.
› Verified 5 days ago
| Entity Name | Retina Consultants Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902800758 PECOS PAC ID: 3375636178 Enrollment ID: O20100607000493 |
News Archive
August marks the start of misery for as many as one in five Americans who suffer from hay fever, also called seasonal allergic rhinitis. That's because ragweed, the main cause of hay fever, begins blooming around mid-August and in one day each plant can produce a million pollen grains that can travel for miles from its source.
Great Lakes NeuroTechnologies announced today they will be using a $1.5M award from NIH to expand their Parkinson's monitoring technology to mobile applications. Repositioning GLNT's Kinesia product line with mobile apps strategically aligns with growing trends in domestic and international healthcare landscapes regarding accessibility, costs, reimbursement, and regulatory policies.
San Diego-based Concerro, Inc., the market leader in enterprise-wide hospital shift and disaster workforce management software, has enhanced its CommandAware® hospital incident management system by adding a new location-based intelligence tool to help clients identify and interact with regional data in a more efficient way.
USA Today reports that President Obama is spending the weekend wrapping up what he himself calls a bruising campaign season. The president, trying to stave off Democratic losses in the U.S. House and Senate, hits three cities today to urge voters to stick with his health care, energy, and economic recovery plans.
Enobia Pharma announced today the initiation of a Phase 2 clinical study of ENB-0040, a bone-targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). The six-month study will assess the safety, efficacy and pharmacokinetics of ENB-0040 in up to 12 children with HPP.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Richard Mark Hatfield, MD Po Box 3970, Charleston, WV 25339-3970 Ph: (304) 346-4400 | Richard Mark Hatfield, MD 331 Laidley St, Ste 301, Charleston, WV 25301-1605 Ph: (304) 346-4400 |
News Archive
August marks the start of misery for as many as one in five Americans who suffer from hay fever, also called seasonal allergic rhinitis. That's because ragweed, the main cause of hay fever, begins blooming around mid-August and in one day each plant can produce a million pollen grains that can travel for miles from its source.
Great Lakes NeuroTechnologies announced today they will be using a $1.5M award from NIH to expand their Parkinson's monitoring technology to mobile applications. Repositioning GLNT's Kinesia product line with mobile apps strategically aligns with growing trends in domestic and international healthcare landscapes regarding accessibility, costs, reimbursement, and regulatory policies.
San Diego-based Concerro, Inc., the market leader in enterprise-wide hospital shift and disaster workforce management software, has enhanced its CommandAware® hospital incident management system by adding a new location-based intelligence tool to help clients identify and interact with regional data in a more efficient way.
USA Today reports that President Obama is spending the weekend wrapping up what he himself calls a bruising campaign season. The president, trying to stave off Democratic losses in the U.S. House and Senate, hits three cities today to urge voters to stick with his health care, energy, and economic recovery plans.
Enobia Pharma announced today the initiation of a Phase 2 clinical study of ENB-0040, a bone-targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). The six-month study will assess the safety, efficacy and pharmacokinetics of ENB-0040 in up to 12 children with HPP.
› Verified 5 days ago
Dr. Paul Frederick Francke, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1220 Lee St E Ste 203, Charleston, WV 25301 Phone: 304-343-4124 Fax: 304-343-4167 | |
Dr. Huseyin Kadikoy, M.D Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1220 Lee St E, Charleston, WV 25301 Phone: 304-388-6630 Fax: 304-388-6629 | |
Dr. Stephen Paul Cassis, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 301 49th St Se, Suite A, Charleston, WV 25304 Phone: 304-925-3937 Fax: 304-925-4336 | |
Dr. Audrey Lilian Hunt, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1220 Lee St E, Charleston, WV 25301 Phone: 304-388-6630 Fax: 304-388-6629 | |
James White Caudill, MD RETIRED Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 501 Summers St, Charleston, WV 25301 Phone: 304-343-3937 Fax: 304-344-3957 | |
Dr. Sara E O'connor, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1306 Kanawha Blvd E, Charleston, WV 25301 Phone: 304-343-4371 Fax: 304-353-0215 |